At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border ...
Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...
The concerns of October 10, 1857, sound remarkably familiar today.
There is still a lot to be learned about the complicated relationship between blood pressure (BP) and glaucoma, and it has taken a while to amass the body of knowledge available today. Some of the ...
Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal ...
Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...
Elizabeth A. Davis MD, FACS | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results